C07D213/04

PSMA-TARGETING COMPOUNDS AND USES THEREOF
20220259161 · 2022-08-18 ·

Compositions and methods for visualizing tissue under illumination with near-infrared radiation, including compounds comprising near-infrared, closed chain, sulfo-cyanine dyes and prostate specific membrane antigen ligands are disclosed.

Conducting reactions in leidenfrost-levitated droplets

The invention generally relates to conducting reactions in Leidenfrost-levitated droplets.

Conducting reactions in leidenfrost-levitated droplets

The invention generally relates to conducting reactions in Leidenfrost-levitated droplets.

INHIBITORS OF HUMAN ATGL

The present invention relates to novel inhibitors of adipose triglyceride lipase (ATGL) having an improved inhibitory activity against human ATGL (hATGL) as well as pharmaceutical compositions comprising these inhibitors, and their therapeutic use, particularly in the treatment or prevention of a lipid metabolism disorder, including, e.g., obesity, non-alcoholic fatty liver disease, type 2 diabetes, insulin resistance, glucose intolerance, hypertriglyceridemia, metabolic syndrome, cardiac and skeletal muscle steatosis, congenital generalized lipodystrophy, familial partial lipodystrophy, acquired lipodystrophy syndrome, atherosclerosis, or heart failure.

BICYCLIC HETEROCYCLIC COMPOUNDS USEFUL AS IRAK4 INHIBITORS

Disclosed are compounds of Formula (I) or a salt or prodrug thereof, wherein: X is CR.sub.4a or N; Y is CR.sub.4b or N; Z is CR.sub.4d or N; provided that zero or 1 of X, Y, and Z is N; and R.sub.1, R.sub.2, R.sub.3, R.sub.4a, R.sub.4b, R.sub.4c, and R.sub.4d are define herein. Also disclosed are methods of using such compounds as modulators of IRAK4, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases, or in the treatment of cancer.

##STR00001##

BICYCLIC HETEROCYCLIC COMPOUNDS USEFUL AS IRAK4 INHIBITORS

Disclosed are compounds of Formula (I) or a salt or prodrug thereof, wherein: X is CR.sub.4a or N; Y is CR.sub.4b or N; Z is CR.sub.4d or N; provided that zero or 1 of X, Y, and Z is N; and R.sub.1, R.sub.2, R.sub.3, R.sub.4a, R.sub.4b, R.sub.4c, and R.sub.4d are define herein. Also disclosed are methods of using such compounds as modulators of IRAK4, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases, or in the treatment of cancer.

##STR00001##

CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE
20220274936 · 2022-09-01 ·

The invention provides compounds of Formula (I), or pharmaceutically acceptable salts thereof:

##STR00001##

The compounds, compositions, methods and kits of the invention are useful for the treatment of pain, cough, itch, and neurogenic inflammation.

SPHINGOLIPID-BASED SELENIUM COMPOUNDS, METHODS FOR THEIR PREPARATION, AND PHARMACEUTICAL USES THEREOF, INCLUDING AS ANTITUMOR AGENTS
20220288109 · 2022-09-15 ·

Ionic conjugates of selenite anions and cationic ceramide analogs are described. For instance, conjugates can comprise ionic conjugates of selenite anions and pyridinium-substituted ceramide analogs. Also described is the use of the ionic conjugates in treating cancer, such as head and neck cancer and brain cancer.

Pyridinium, quinolinium, acridinium, pyrylium, chromenylium or xanthylizum reactive desorption and/or laser ablation ionization matrices and use thereof

The present disclosure concerns use of compounds of formula I, or salts thereof, as reactive matrices for desorption and laser ablation ionization spectrometry. The disclosure further concerns compounds of formula II, or salts thereof, and use of compounds of formula II or III, or salts thereof. ##STR00001##

Pyridinium, quinolinium, acridinium, pyrylium, chromenylium or xanthylizum reactive desorption and/or laser ablation ionization matrices and use thereof

The present disclosure concerns use of compounds of formula I, or salts thereof, as reactive matrices for desorption and laser ablation ionization spectrometry. The disclosure further concerns compounds of formula II, or salts thereof, and use of compounds of formula II or III, or salts thereof. ##STR00001##